Table 1. Baseline characteristics of Intent to Treat (ITT) and evaluable patients.
| Parameter | ITT | Evaluable |
|---|---|---|
| Number (%) | Number (%) | |
| Ethnicity | ||
| South Asian (Indian) | 143 (100%) | 126 (100%) |
| Gender | ||
| Male | 73 (51.0%) | 65 (51.6%) |
| Female | 70 (49.0%) | 61 (48.4%) |
| Age | ||
| Min | 25 | 24 |
| Max | 75 | 72 |
| Median | 50 | 50 |
| Cancer Types and Organs | ||
| Bone | 4 (2.1%) | 3 (2.4%) |
| Breast | 26 (18.2%) | 21 (16.7%) |
| Cervical | 5 (3.5%) | 5 (3.9%) |
| Colorectal | 14 (9.8%) | 14 (11.1%) |
| Oesophagus | 2 (1.4%) | 2 (1.6%) |
| Gastric | 7 (4.9%) | 6 (4.8%) |
| Head and Neck | 36 (25.2%) | 31 (24.6%) |
| Hepatobiliary | 7 (4.9%) | 6 (4.8%) |
| Kidney | 4 (2.8%) | 4 (3.2%) |
| Lung | 7 (4.9%) | 5 (4.0%) |
| Neuroendocrine tumors | 3 (2.1%) | 3 (2.4%) |
| Ovarian | 9 (6.3%) | 8 (6.3%) |
| Pancreatic | 8 (5.6%) | 8 (6.3%) |
| Prostate | 1 (0.7%) | 1 (0.8%) |
| Sarcoma | 5 (3.5%) | 4 (3.2%) |
| Skin | 3 (1.8%) | 3 (2.4%) |
| Testes | 2 (1.2%) | 2 (1.6%) |
| Grade of Tumor | ||
| 1 (Well-differentiated) | 13 (9.1%) | 11 (8.7%) |
| 2 (Moderately differentiated) | 54 (37.8%) | 50 (39.7%) |
| 3 (Poorly differentiated/undifferentiated) | 52 (36.4%) | 43 (34.1%) |
| (Grade unevaluable) | 24 (16.8%) | 22 (17.5%) |
| Total Prior Lines of Therapy | ||
| 1–2 | 38 (26.6%) | 36 (28.6%) |
| 3–4 | 61 (42.7%) | 52 (41.3%) |
| ≥ 5 | 44 (30.8%) | 38 (30.2%) |